TRACLEER Australia - English - Department of Health (Therapeutic Goods Administration)

tracleer

actelion pharmaceuticals australia pty limited - bosentan monohydrate -

TRACLEER TABLET 125 mg Singapore - English - HSA (Health Sciences Authority)

tracleer tablet 125 mg

johnson & johnson international (singapore) pte ltd - bosentan monohydrate 129.082mg eqv bosentan - tablet, film coated - 125 mg - bosentan monohydrate 129.082mg eqv bosentan 125 mg

TRACLEER TABLET 62.5 mg Singapore - English - HSA (Health Sciences Authority)

tracleer tablet 62.5 mg

johnson & johnson international (singapore) pte ltd - bosentan monohydrate 64.541mg eqv bosentan - tablet, film coated - 62.5 mg - bosentan monohydrate 64.541mg eqv bosentan 62.5 mg

SODIUM IODIDE [I-131] INJECTION 74 MBqml Singapore - English - HSA (Health Sciences Authority)

sodium iodide [i-131] injection 74 mbqml

ge healthcare pte. ltd. - sodium iodide [i-131] - injection - 74 mbq/ml - sodium iodide [i-131] 74 mbq/ml

SODIUM IODIDE [I-131] INJECTION 925 MBqml Singapore - English - HSA (Health Sciences Authority)

sodium iodide [i-131] injection 925 mbqml

ge healthcare pte. ltd. - sodium iodide [i-131] - injection - 925 mbq/ml - sodium iodide [i-131] 925 mbq/ml

Bosentan Dr. Reddy’s 62.5mg Film-Coated Tablets United Kingdom - English - myHealthbox

bosentan dr. reddy’s 62.5mg film-coated tablets

dr. reddy’s laboratories (uk) ltd. - bosentan - film-coated tablet - 62.5mg - other antihypertensives - treatment of pulmonary arterial hypertension (pah) to improve exercise capacity and symptoms in patients with who functional class iii. efficacy has been shown in: • primary (idiopathic and heritable) pulmonary arterial hypertension • pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease • pulmonary arterial hypertension associated with congenital systemic-topulmonary shunts and eisenmenger’s physiology

Bosentan Dr. Reddy’s 125mg Film-Coated Tablets United Kingdom - English - myHealthbox

bosentan dr. reddy’s 125mg film-coated tablets

dr. reddy’s laboratories (uk) ltd. - bosentan - film-coated tablet - 125mg - other antihypertensives - treatment of pulmonary arterial hypertension (pah) to improve exercise capacity and symptoms in patients with who functional class iii. efficacy has been shown in: • primary (idiopathic and heritable) pulmonary arterial hypertension • pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease • pulmonary arterial hypertension associated with congenital systemic-topulmonary shunts and eisenmenger’s physiology

Stayveer European Union - English - EMA (European Medicines Agency)

stayveer

janssen-cilag international nv - bosentan (as monohydrate) - hypertension, pulmonary; scleroderma, systemic - other antihypertensives - treatment of pulmonary arterial hypertension (pah) to improve exercise capacity and symptoms in patients with world health organization (who) functional class iii. efficacy has been shown in:primary (idiopathic and familial) pah;pah secondary to scleroderma without significant interstitial pulmonary disease;pah associated with congenital systemic-to-pulmonary shunts and eisenmenger’s physiology.some improvements have also been shown in patients with pah who functional class ii.stayveer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital-ulcer disease.

Tracleer European Union - English - EMA (European Medicines Agency)

tracleer

janssen-cilag international n.v.   - bosentan (as monohydrate) - scleroderma, systemic; hypertension, pulmonary - antihypertensives, - treatment of pulmonary arterial hypertension (pah) to improve exercise capacity and symptoms in patients with who functional class iii.efficacy has been shown in: , primary (idiopathic and familial) pah;, pah secondary to scleroderma without significant interstitial pulmonary disease;, pah associated with congenital systemic-to-pulmonary shunts and eisenmenger's physiology. , some improvements have also been shown in patients with pah who functional class ii. tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.,